万洲(00288.HK)逆市急弹10%突破百天线 首三季生物公允价值调整前盈利年增8.5%
万洲国际(00288.HK)首三季生物公允价值调整前盈利年增8.5%,摩通绩後重申万洲「增持」评级,目标价降至10.6元,仍远高於现价。该股今早扭两连跌,一举升破四条移动平均线(百天线为6.75元),现造6.88元即市高位,急弹10%,成交达4,954万股,已超过昨天全日成交量4,295万股。
万洲公布,按生物公允价值调整前计算,今年首三季纯利按年升8.5%至8.9亿美元。期内,总营收按年升9.2%至187.67亿美元;息税折旧及摊销前利润按年升近13%至19.53亿美元。
若按生物公允价值调整後计算,万洲首三季纯利按年跌13%至7.59亿美元;期内息税折旧及摊销前利润按年微跌0.6%至17.88亿美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.